Stockysis

Article

BTIG Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $9

Benzinga Newsdesk | Mar 02, 2026 12:41 | Source: www.benzinga.com

BTIG analyst Jeet Mukherjee maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target from $26 to $9.

Comments